Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 14/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21986776 | 0.88 | CYP4F2 (0.37) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21986774 | 0.88 | CYP4F2 (0.39) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21986816 | 0.85 | ATR (0.36) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL31586146 | 0.84 | PDE8B (0.40) | PDE8BCYP4F2CYP4A11GAARET | |
| SCHEMBL21550760 | 0.81 | CYP4F2 (0.39) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21986741 | 0.81 | CYP4F2 (0.37) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL31585878 | 0.78 | CYP4F2 (0.36) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21986732 | 0.76 | CYP4F2 (0.38) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21986824 | 0.76 | ATR (0.36) | PDE8BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21986862 | 0.75 | CYP4F2 (0.33) | PDE8BCYP4F2CYP4A11GAAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | PDE8B 3451/4885CYP4F2 4162/4885CYP4A11 3116/4885 |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | PDE8B 3451/4885CYP4F2 4162/4885CYP4A11 3116/4885 |
| US-11713311-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | PDE8B 3451/4885CYP4F2 4162/4885CYP4A11 3116/4885 |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | PDE8B 3451/4885CYP4F2 4162/4885CYP4A11 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.